Claims for Patent: 9,630,946

Summary for Patent: 9,630,946

Title:	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Abstract:	The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
Inventor(s):	Lu; Quinhong (Suffern, NY), Ku; Mannching Sherry (Thiells, NY), Chew; Warren (Pierrefonds, CA), Cheal; Gloria (Beaconsfield, CA), Hadfield; Anthony F. (St. Petersburg, FL), Mirmehrabi; Mahmoud (Laval, CA)
Assignee:	WYETH LLC (New York, NY)
Application Number:	14/825,612
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,630,946
Patent Claims:	1. A method of increasing oral absorption of neratinib, comprising: formulating neratinib as anhydrous neratinib maleate salt (Form I), wherein the anhydrous neratinib maleate salt (Form I) is prepared according to a method comprising: i) mixing (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and maleic acid in a water-alcohol solution at a temperature in the range of between about 50.degree. C. to about 60.degree. C.; ii) cooling said solution to a temperature of about 40.degree. C. and maintaining the cooled solution at about 40.degree. C. for about 12 hours to precipitate the maleate salt; iii) further cooling the cooled solution to room temperature (about 25.degree. C.) over a minimum of 4 hours and maintaining the further cooled solution at room temperature (about 25.degree. C.) for at least 2 hours; and iv) filtering the maintained, further cooled solution to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate is (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate; and v) drying the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate under vacuum at a temperature greater than 30.degree. C. for 12 to 48 hours to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I; wherein the anhydrous neratinib maleate salt (Form I) formulation produces at least a two-fold greater AUC (area under concentration), relative to neratinib in a free base formulation; and wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 12.61, 14.65, and 15.75. 2. The method of claim 1, wherein the drying step comprises drying the (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, monohydrate at 50.degree. C., 10 mm Hg for 24 hours to obtain the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I. 3. The method of claim 1, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 10.20, 12.24, 12.61, 14.65, 15.75, 17.33, 18.64, 19.99, 20.66, 21.32, 22.30, 23.18, 24.10, 24.69, 25.49, 26.09, 26.54, 27.52, 28.62, and 29.43. 4. The method of claim 3, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, has substantially the X-ray diffraction pattern as shown in FIG. 6. 5. A method of mitigating interaction with emetic receptors associated with neratinib therapy in mammals, comprising: formulating neratinib as anhydrous neratinib maleate salt (Form I), wherein the anhydrous neratinib maleate salt (Form I) is prepared according to a method comprising: i) mixing (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and maleic acid in a water-alcohol solution at a temperature in the range of between about 50.degree. C. to about 60.degree. C.; ii) cooling said solution to a temperature of about 40.degree. C. and maintaining the cooled solution at about 40.degree. C. for about 12 hours to precipitate the maleate salt; iii) further cooling the cooled solution to room temperature (about 25.degree. C.) over a minimum of 4 hours and maintaining the further cooled solution at room temperature (about 25.degree. C.) for at least 2 hours; and iv) filtering the maintained, further cooled solution to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate is (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate; and v) drying the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate under vacuum at a temperature greater than 30.degree. C. for 12 to 48 hours to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I; wherein the anhydrous neratinib maleate salt (Form I) formulation mitigates interactions with emetic receptors relative to neratinib in a free base formulation; and wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 12.61, 14.65, and 15.75. 6. The method of claim 5, wherein the drying step comprises drying the (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, monohydrate at 50.degree. C., 10 mm Hg for 24 hours to obtain the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I. 7. The method of claim 5, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 10.20, 12.24, 12.61, 14.65, 15.75, 17.33, 18.64, 19.99, 20.66, 21.32, 22.30, 23.18, 24.10, 24.69, 25.49, 26.09, 26.54, 27.52, 28.62, and 29.43. 8. The method of claim 7, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, has substantially the X-ray diffraction pattern as shown in FIG. 6. 9. A method of treating diarrhea associated with neratinib therapy, comprising: formulating neratinib as anhydrous neratinib maleate salt (Form I), wherein the anhydrous neratinib maleate salt (Form I) is prepared according to a method comprising: i) mixing (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and maleic acid in a water-alcohol solution at a temperature in the range of between about 50.degree. C. to about 60.degree. C.; ii) cooling said solution to a temperature of about 40.degree. C. and maintaining the cooled solution at about 40.degree. C. for about 12 hours to precipitate the maleate salt; iii) further cooling the cooled solution to room temperature (about 25.degree. C.) over a minimum of 4 hours and maintaining the further cooled solution at room temperature (about 25.degree. C.) for at least 2 hours; and iv) filtering the maintained, further cooled solution to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate is (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate; and v) drying the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate under vacuum at a temperature greater than 30.degree. C. for 12 to 48 hours to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I; wherein the anhydrous neratinib maleate salt (Form I) formulation reduces diarrhea, relative to neratinib in a free base formulation; and wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 12.61, 14.65, and 15.75. 10. The method of claim 9, wherein the drying step comprises drying the (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, monohydrate at 50.degree. C., 10 mm Hg for 24 hours to obtain the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I. 11. The method of claim 9, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 10.20, 12.24, 12.61, 14.65, 15.75, 17.33, 18.64, 19.99, 20.66, 21.32, 22.30, 23.18, 24.10, 24.69, 25.49, 26.09, 26.54, 27.52, 28.62, and 29.43. 12. The method of claim 11, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, has substantially the X-ray diffraction pattern as shown in FIG. 6. 13. A method of treating cancer, comprising: formulating neratinib as anhydrous neratinib maleate salt (Form I), wherein the anhydrous neratinib maleate salt (Form I) is prepared according to a method comprising: i) mixing (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and maleic acid in a water-alcohol solution at a temperature in the range of between about 50.degree. C. to about 60.degree. C.; ii) cooling said solution to a temperature of about 40.degree. C. and maintaining the cooled solution at about 40.degree. C. for about 12 hours to precipitate the maleate salt; iii) further cooling the cooled solution to room temperature (about 25.degree. C.) over a minimum of 4 hours and maintaining the further cooled solution at room temperature (about 25.degree. C.) for at least 2 hours; and iv) filtering the maintained, further cooled solution to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate is (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate; and v) drying the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate monohydrate under vacuum at a temperature greater than 30.degree. C. for 12 to 48 hours to obtain crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I; wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 12.61, 14.65, and 15.75. 14. The method of claim 13, wherein the drying step comprises drying the (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, monohydrate at 50.degree. C., 10 mm Hg for 24 hours to obtain the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I. 15. The method of claim 13, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, is characterized by X-ray diffraction peaks at the following angles (.+-.0.20.degree.) of 2Theta in its X-ray diffraction pattern comprising 6.16, 7.38, 8.75, 10.20, 12.24, 12.61, 14.65, 15.75, 17.33, 18.64, 19.99, 20.66, 21.32, 22.30, 23.18, 24.10, 24.69, 25.49, 26.09, 26.54, 27.52, 28.62, and 29.43. 16. The method of claim 15, wherein the crystalline (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide maleate, anhydrous, Form I, has substantially the X-ray diffraction pattern as shown in FIG. 6.